anti-PD-1 antibody + sorafenib

Combination drug composed of an **anti-PD-1 monoclonal antibody** (such as nivolumab, pembrolizumab, or tislelizumab) and **sorafenib** (a small-molecule multi-kinase inhibitor). Anti-PD-1 antibodies work by **blocking the programmed cell death protein 1 (PD-1) receptor** on T cells, thereby enhancing immune responses against cancer cells. Sorafenib inhibits multiple kinases involved in tumor proliferation and angiogenesis, primarily targeting **Raf kinases, vascular endothelial growth factor receptors, platelet-derived growth factor receptors, and others**. This combination is explored as a therapy for advanced hepatocellular carcinoma, aiming to provide both direct anti-tumor effects and immune-mediated anti-cancer activity[1][4][12][13].

Other names

anti-PD-1 antibody + sorafenibanti-PD-1 monoclonal antibody + sorafenib